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Coronavirus defective RNAs (D-RNAs) have been used for site-directed mutagenesis of coronavirus genomes
and for expression of heterologous genes. D-RNA CD-61 derived from the avian coronavirus infectious
bronchitis virus (IBV) was used as an RNA vector for the expression of chicken gamma interferon (chIFN-).
D-RNAs expressing chIFN- were shown to be capable of rescue, replication, and packaging into virions in a
helper virus-dependent system following electroporation of in vitro-derived T7 RNA transcripts into IBV-
infected cells. Secreted chIFN-, under the control of an IBV transcription-associated sequence derived from
gene 5 of the Beaudette strain, was expressed from two different positions within CD-61 and shown to be
biologically active. In addition, following infection of 10-day-old chicken embryos with IBV containing D-RNAs
expressing chIFN-, the allantoic fluid was shown to contain biologically active chIFN-, demonstrating that
IBV D-RNAs can express heterologous genes in vivo.
Infectious bronchitis virus (IBV) is a highly infectious and
economically important pathogen of chickens that causes re-
spiratory disease, diminished growth rate, and substantial de-
cline in egg production. Although infectious bronchitis is con-
sidered primarily a disease of the respiratory system, strains of
IBV have wide and variable tropisms and the clinical manifes-
tations of the disease can be diverse (9). Genetically very
similar viruses cause disease in turkeys (6) and pheasants (7).
IBV is a group 3 member of the genus Coronavirus of the
family Coronaviridae in the order Nidovirales (12), being an
enveloped RNA virus with an unsegmented, 5-end-capped,
3-end-polyadenylated, single-stranded, positive-sense RNA
genome of 27,608 nucleotides (nt) (4). Coronaviruses produce
a 3-coterminal nested set of subgenomic mRNAs (sg mRNAs)
that are polycistronic. These are produced by a discontinuous
transcription process during synthesis of the negative strand
and contain identical 5 ends due to the addition of a leader
sequence derived from the 5 end of the genomic RNA
(gRNA) (35, 36). Preceding the body sequence of each sg
mRNA is a consensus sequence, the transcription-associated
sequence (TAS) (15), involved in the acquisition of the leader
sequence. All coronavirus envelopes contain at least three
membrane proteins, the spike glycoprotein, a small membrane
protein, and an integral membrane protein. In addition, the
coronavirus virion also contains a nucleocapsid protein that
interacts with the gRNA.
Coronavirus defective RNAs (D-RNAs), which lack large
parts of the genome, are produced following virus passage at a
high multiplicity of infection. While all D-RNAs contain cis-
acting sequences necessary for replication, only a subset of
D-RNAs contain sequences necessary for packaging into viri-
ons in the presence of a helper virus. Coronavirus D-RNAs
have been used for site-directed mutagenesis of the virus ge-
nome (25) and for expression of heterologous genes (1, 2, 13,
17, 20, 22, 39, 42, 43).
Cytokines are regulatory proteins that act as a communica-
tion network between cells throughout immunological devel-
opment. Avian homologues of several mammalian cytokines
have been isolated, including chicken gamma interferon
(chIFN-) (10). Mammalian IFN- is a pleiotropic cytokine
initially produced by natural killer cells, during immune induc-
tion, and then by committed T helper 1 (Th1) cells as a regu-
lator and effector molecule for driving inflammatory responses
(for a review, see reference 8). IFN- has a major role in
activating antiviral immune responses through augmentation
of major histocompatibility complex expression on antigen-
presenting cells for interaction with T cells, stimulation of
antibody (Ab) formation, promotion of Ab isotype class
switching, and development of cytotoxic T cells. Several studies
have been undertaken to investigate the in vivo potential of
IFN- as a vaccine adjuvant. Coadministration of bovine
IFN- with vesicular stomatitis virus G glycoprotein to cattle
resulted in an increased formation of protective Ab against
vesicular stomatitis virus (41). In a mouse model, fusion of
IFN- to human immunodeficiency virus gp120 resulted in
enhanced primary Ab responses against gp120, enhanced an-
tigen-specific T-cell proliferation, and IFN- production (26).
The use of recombinant feline IFN- as a vaccine adjuvant
increased Ab responses against rabies virus and calicivirus an-
tigens (37).
The role of recombinant chIFN- as an adjuvant and ther-
apeutic agent has been investigated. Coadministration of
chIFN- with sheep red blood cells (SRBCs) resulted in an
increased secondary Ab response with amounts of SRBCs 10-
fold smaller than the dose of SRBCs given alone (23, 24).
Administration of recombinant chIFN- prior to challenge
with avian coccidia resulted in decreased intracellular sporo-
zoite development and oocyst production, with an enhanced
level of body weight gain (21). chIFN- had an adjuvant effect,
reducing parasite replication, when used in a DNA vaccine
regimen against Eimeria acervulina (27). Coexpression of New-
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castle disease virus antigens with chIFN- by using fowlpox
virus resulted in an earlier Ab response, with the best protec-
tive immune response of the recombinant fowlpox virus vac-
cines (32).
In this study we describe both the in vitro and in ovo expres-
sion of biologically active chIFN- from an IBV D-RNA. We
demonstrate for the first time the expression of a chicken
cytokine from an IBV D-RNA and the in ovo expression of a
biologically active heterologous gene from an IBV D-RNA.
MATERIALS AND METHODS
Cells and viruses. IBV Beaudette was grown in 11-day-old embryonated do-
mestic fowl eggs, harvested from allantoic fluid 24 h postinfection, and used as
helper virus for the rescue of IBV D-RNAs (31). IBV was passaged and titrated
on primary chick kidney (CK) cells (30). HD11 cells, an avian leukosis virus
(MC29)-transformed cell line (3), were cultured in RPMI 1640 medium (Life
Technologies) containing 2.5% fetal calf serum, 2.5% chick serum, 10% tryptose
phosphate broth, 20 mM L-glutamine, 0.225% NaHCO3, 1 U of penicillin/ml, and
1 g of streptomycin/ml.
Oligonucleotides. The oligonucleotides used in this work were obtained from
Invitrogen and are listed in Table 1.
Recombinant DNA techniques. Standard procedures were used to produce
recombinant DNA (33), or methods were according to the manufacturers’ in-
structions.
Construction of TAS-chIFN- gene cassette. A TAS-chIFN- cassette was
produced by PCR for insertion into the IBV D-RNA CD-61 cDNA sequence in
pIBV-Vec (13). Oligonucleotides IBV5IFN-START and SmaIIFN--END,
corresponding to the 5 end and complementary to the 3 end, respectively, of the
chIFN- sequence, were used to generate the TAS-chIFN- cassette. Oligonu-
cleotide IBV5IFN-START contained the restriction endonuclease SmaI and
PmaCI sites, the Beaudette-derived gene 5 TAS (39), and the first 15 nt of the
chIFN- sequence. Oligonucleotide SmaIIFN--END consisted of the last 15 nt
(complementary) of the chIFN- gene, including the termination codon, fol-
lowed by a SmaI site. The chIFN- sequence was amplified by PCR by using
Taq/Pwo DNA polymerase (Hybaid) from plasmid pGEM-T-IFN- (19) con-
taining a cDNA derived from chIFN- mRNA. The TAS-chIFN- cassette was
digested with XmaI and ligated into XmaI-digested pBluescript II SK() (Strat-
agene), resulting in pBS-IFN-ENDS, in which the TAS-chIFN- sequence
was verified by sequence analysis. The TAS-chIFN- cassette was removed from
pBS-IFN-ENDS by using PmaCI and SmaI and inserted into either the
PmaCI site or the SnaBI site in the CD-61 sequence of pIBV-Vec.
In vitro rescue of chIFN--containing D-RNAs by IBV Beaudette. In vitro
T7-derived D-RNA transcripts were synthesized from 1 g of plasmid DNA and
electroporated into IBV-infected CK cells (passage 0 [P0]) (39). Virus V1 in 1 ml
of cell medium was used to infect CK cells, and viruses V2 to V6 were serially
passaged every 24 h for six passages (P1 to P6).
In ovo rescue of chIFN--containing D-RNAs. Cell medium (100 l) from P3
CK cells, corresponding to peak D-RNA levels, was used to infect 10-day-old
Rhode Island Red specific-pathogen-free embryos. The infected embryos were
incubated at 37°C for 16 h and cooled to 4°C overnight. Allantoic fluid was
collected from the infected eggs, centrifuged at 1,500  g for 10 min, and stored
at 70°C. Allantoic fluid (100 l) containing IBV and any potential D-RNA was
used to infect CK cells.
Identification of IBV-derived RNAs. Total cytoplasmic RNA was extracted
from infected CK cells by using RNeasy (Qiagen) and electrophoresed in dena-
turing 1% agarose–2.2 M formaldehyde gels. The RNAs were Northern blotted
onto Hybond XL nylon membranes (Amersham), and IBV-derived RNAs were
detected with probes covalently labeled with psoralen-biotin (BrightStar; Am-
bion) (13). The probes were hybridized to the RNAs at 42°C for 16 h, detected
with streptavidin-alkaline phosphatase conjugate in the presence of an alkaline
phosphatase 1,2-dioxetane chemiluminescent substrate (CDPStar and BrightStar
Biodetect; Ambion), and exposed to film at room temperature for 2 h. An
IBV-specific 309-nt 3-untranslated region (UTR) probe, corresponding to the
last 309 nt of the 3 end of the IBV genome, was used to detect all IBV-derived
RNA species, including IBV-derived D-RNAs (13). A 209-nt 5 IBV-specific
probe, produced by PCR with oligonucleotides BG-67 and BG-2 (Table 1)
corresponding to nt 265 to 474 within the 5 UTR of the Beaudette genome, was
used to detect IBV gRNA and D-RNAs. A 360-nt chIFN--specific probe,
produced by PCR with primers IFN/3 and IFN/7 (Table 1), was used to detect
RNAs containing the chIFN- sequence.
chIFN- bioassays and neutralization assays. The chIFN- bioassays and
neutralization assays were carried out as described by Lawson et al. (19). Essen-
tially, triplicate samples (200 l) of serially diluted CK cell medium or allantoic
fluid, either from mock-infected embryos or embryos infected with IBV, were
added to 4  104 HD11 cells in 96-well flat-bottomed plates. Recombinant
chIFN-, prepared as described by Lawson et al. (19), was serially diluted two-
fold and used as a positive control. chIFN- neutralization assays were carried
out by using an anti-chIFN- neutralizing monoclonal Ab (MAb), 1E-12 (18),
and an anti-bovine granulocyte-macrophage colony-stimulating factor polyclonal
Ab, CC305 (kindly provided by Paul Sopp, Institute for Animal Health, Comp-
ton, United Kingdom). Both antibodies were diluted 1:1,000 and incubated with
CK cell medium and allantoic fluid samples for 2 h at room temperature before
being added to HD11 cells. For controls, all samples were also preincubated with
the isotype control Ab CC305 and media alone. All HD11 cells were incubated
at 41°C in 5% CO2 for 48 h for the chIFN- bioassays.
Nitric oxide (NO) produced from HD11 cells, resulting from induction with
chIFN-, was measured in HD11 cell medium (100 l) as nitrite (NO2) by using
a modification of the Griess assay described by Lawson et al. (19) and a Spectra
Max 250 enzyme-linked immunosorbent assay reader (Molecular Devices, Wok-
ingham, United Kingdom). The amount of NO present in the HD11 cell media
was expressed as the concentration of NO2 (millimolar) for the chIFN- bio-
assays or as the optical density at 543 nm for the neutralizing assays.
RESULTS
D-RNAs containing TAS-chIFN-. Expression of heterolo-
gous genes from coronavirus D-RNAs requires the genes to be
under the control of a TAS for synthesis of an sg mRNA. The
chIFN- sequence was placed under the control of the IBV
Beaudette gene 5 TAS (39) by using PCR and a chIFN-
mRNA-derived cDNA (19), generating a TAS-chIFN- cas-
sette for IBV-controlled expression. The gene 5 TAS was orig-
inally chosen for expression of heterologous genes because it
has the shortest sequence between the 3 end of the TAS and
the AUG of open reading frame (ORF) 5a and also because
the Beaudette sg mRNA 5 is one of the most abundantly
TABLE 1. Oligonucleotides used for generation of TAS-chIFN- cassette and hybridization probes
Oligonucleotide Sequencea Positionb Polarity
IBV5IFN-START TCC CCC GGG CAC GTG TTT TAC TTA ACA AAA ACT TAA CAA
ATA CGG ACG ATG ACT TGC CAG ACT
NA 
SmallFN--END ACC CCC GGG GGT TAG CAA TTG CAT CT NA 
BG-67 GGC TGG TTC GAG TGC GAG Beaudette 265–282 
BG-2 TCA GGG GTT GTT TGG CAC T Beaudette 455–473 
IFN/3 ATG ACT TGC CAG ACT TAC AA chIFN- 1–20 
IFN/7 CAG GTC CAT GAT ATC TTT CAC chIFN- 340–360 
a Underlined sequences correspond to the IBV sequence. Nucleotides marked in bold correspond to the IBV canonical TAS, and those in italics correspond to
restriction endonuclease sites used for cloning.
b The positions of the nucleotides refer to the IBV Beaudette sequence (4) or the chIFN- sequence (10). NA, not applicable.
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expressed sg mRNAs (39). The TAS-chIFN- cassette was
initially inserted into pBluescript II SK() under the control of
the T7 promoter. A protein with a size corresponding to that of
chIFN- was produced in vitro by using the TNT T7 coupled
wheat germ extract system (Promega; data not shown), indi-
cating that a product of the expected size could be produced
from the TAS-chIFN- cassette.
Two restriction endonuclease sites, PmaCI and SnaBI,
within the IBV D-RNA CD-61 have been used for the expres-
sion of heterologous genes (13, 39). The PmaCI site is within
domain III of CD-61 and not within the D-RNA-specific ORF
(31), whereas the SnaBI site, within domain II of CD-61, in-
terrupts the D-RNA-specific ORF (Fig. 1B). The TAS-
chIFN- cassette excised from pBS-IFN-ENDS was in-
serted into the PmaCI site or the SnaBI site of the CD-61
sequence in pIBV-Vec. Four plasmids, pIBV-Vec-IFN-
PmaCI and pIBV-Vec-IFN-SnaBI, with the TAS-chIFN-
gene cassette in the correct orientation, and pIBV-Vec--
NFIPmaCI and pIBV-Vec--NFISnaBI, with the TAS-
chIFN- gene cassette in the opposite (incorrect) orientation,
were identified for generating D-RNAs (Fig. 1).
In vitro rescue of chIFN--containing D-RNAs. In vitro T7-
derived transcripts of D-RNAs IBV-Vec-IFN-PmaCI, IBV-
Vec-IFN-SnaBI, IBV-Vec--NFIPmaCI, and IBV-Vec--
NFISnaBI were electroporated into IBV-infected CK cells,
and progeny virus with D-RNAs was serially passaged on CK
cells (P0 to P6). Northern blot analyses using the IBV 3-UTR
and chIFN- probes on RNA isolated from P3 cells identified
an RNA species of 6.8 kb (Fig. 2). This RNA was not present
in cells infected with IBV only and corresponded in size to the
in vitro T7-derived D-RNA transcript. The chIFN--specific
probe did not hybridize to IBV gRNA or sg mRNAs, indicat-
ing that the 6.8-kb RNA represented D-RNAs containing the
TAS-chIFN- sequence. As expected, the chIFN- probe de-
tected D-RNAs IBV-Vec--NFIPmaCI and IBV-Vec--
NFISnaBI, with the TAS-chIFN- sequence in the opposite
orientation. The chIFN- probe also detected two other RNAs
of 1.7 kb (Fig. 2B, lane 3) and 5 kb (Fig. 2B, lane 4) following
the rescue of D-RNAs IBV-Vec-IFN-PmaCI and IBV-Vec-
IFN-SnaBI, respectively, in addition to the 6.8-kb D-RNA.
These RNAs corresponded to the expected sizes of chIFN-
mRNAs expressed from the TAS-chIFN- sequence in the
D-RNAs. The IBV-Vec-IFN-PmaCI 1.7-kb chIFN- mRNA
was routinely observed in smaller amounts than the IBV-Vec-
IFN-SnaBI 5-kb chIFN- mRNA. The IBV 3-UTR probe
detected RNAs larger than the 6.8-kb D-RNA and the 7.3-kb
IBV sg mRNA 2 (Fig. 2A) which were not detected by the
chIFN- probe (Fig. 2B). These RNAs were shown, by using
Northern blot analysis and an IBV 5-UTR probe (Fig. 3), to
be new IBV-derived D-RNAs not containing the TAS-
chIFN- sequence.
To investigate the rescue profile of the D-RNAs, Northern
blot analyses were carried out on RNA isolated from P0 to P6
CK cells containing D-RNAs IBV-Vec-IFN-PmaCI and IBV-
Vec-IFN-SnaBI by using the IBV 5-UTR, 3-UTR, and
chIFN- probes (Fig. 3). The 6.8-kb D-RNAs were detected by
the two IBV probes in RNA isolated from P1 to P6 CK cells
(Fig. 3A, B, D, and E), and analyses using the chIFN- probe
confirmed that they contained the chIFN- sequence (Fig. 3C
and F). Both D-RNAs, irrespective of whether the chIFN-
sequence was inserted into the PmaCI or SnaBI site, were
initially detected at P1 and increased in amount upon serial
passage, with the largest amount in P4 CK cells, after which the
amount of D-RNA decreased.
RNAs larger than the 6.8-kb chIFN--containing D-RNA
and the IBV sg mRNA 2 were detected from P3 to P6 by using
both IBV probes. The use of the IBV 5 probe indicated that
the RNAs corresponded to new IBV-derived D-RNAs (Fig.
3A, B, D, and E). The new D-RNAs did not contain the
chIFN- sequence (Fig. 3C and F), indicating that they were
derived from IBV gRNA, and were observed in increasing
amounts in RNA isolated from P3 to P6 cells, with concomitant
gradual loss of the 6.8-kb chIFN--containing D-RNAs (Fig.
3).
Analysis of P3-derived RNA following the rescue of D-RNA
FIG. 1. Schematic diagrams of the IBV D-RNAs containing the
TAS-chIFN- sequence. (A) pIBV-Vec showing the PmaCI and SnaBI
sites within CD-61 for insertion of heterologous genes. HR, hepatitis
delta virus antigenomic ribozyme. (B) IBV D-RNA CD-61, showing
the positions of the restriction sites. The BamHI site was used for
determining the orientation of inserts. The TAS-chIFN- gene cassette
was used for insertion into CD-61. The 998-amino-acid CD-61-specific
ORF (30, 31) is indicated as a thick black line. (C) The D-RNAs
resulting from insertion of the TAS-chIFN- cassette into the two
restriction endonuclease sites, in both orientations, within CD-61. The
T7 promoter, HR, and T7 termination sequences of pIBV-Vec (13)
and the TAS-chIFN- sequences are as indicated in panel A. The
chIFN- mRNAs of 1.7 and 5.0 kb derived from D-RNAs IBV-Vec-
IFN-PmaCI and IBV-Vec-IFN-SnaBI, respectively, are indicated as
black arrows.
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IBV-Vec-IFN-SnaBI identified a 5-kb D-RNA-derived
chIFN- mRNA. This mRNA was detected in RNA from P1 to
P6 CK cells containing IBV-Vec-IFN-SnaBI, with the
amounts detected varying in accordance with the amounts of
D-RNA present, the largest amount being detected at P4 (Fig.
3F). An RNA corresponding to the IBV-Vec-IFN-PmaCI
1.7-kb chIFN- mRNA was not detected following serial pas-
sage of the D-RNA (Fig. 3C). However, from the amounts of
the RNA detected, the most likely explanation for this result
was that the amount of the 1.7-kb chIFN- mRNA was below
the detection level of the analysis.
The Northern blot analyses showed that the two chIFN--
containing D-RNAs with the TAS-chIFN- insert in the cor-
rect orientation were rescued in IBV-infected CK cells upon
serial passage. The analyses showed that D-RNA-derived
chIFN- mRNAs were transcribed, irrespective of the position
of the TAS-chIFN- insert, from the D-RNAs.
Analysis of chIFN- expression from D-RNAs. The North-
ern blot analyses showed that D-RNAs containing the TAS-
chIFN- sequences in the correct orientation were rescued
upon serial passage, but the analyses could not show whether
biologically active chIFN- was expressed. The biological assay
for IFN- is based on the fact that macrophages stimulated
with IFN- produce NO, along with other reactive nitrogen
species, as one of several mechanisms to destroy intracellular
pathogens. The chIFN- bioassay involves stimulation of
HD11 cells, a chicken macrophage cell line (3), with chIFN-
for the induction of NO, which accumulates as stable and
quantifiable NO2
 in the HD11 culture medium.
Cell medium from the P0 to P6 CK cells, previously shown to
contain the D-RNAs containing chIFN-, was assayed for
chIFN- activity. Medium from cells containing D-RNAs IBV-
Vec-IFN-PmaCI and IBV-Vec-IFN-SnaBI induced signifi-
cantly larger amounts of NO, following stimulation of HD11
FIG. 2. Northern blot analysis of IBV-specific RNAs following rescue of chIFN--containing D-RNAs. Following electroporation of IBV-
infected CK cells with in vitro T7-derived D-RNAs, progeny virus and D-RNAs were serially passaged (P0 to P6) on CK cells and total cytoplasmic
RNA was extracted. RNA from P3 cells was electrophoresed in denaturing formaldehyde-agarose gels and subjected to Northern blotting, and
IBV-derived RNAs were detected by using the 309-bp IBV 3-UTR probe (A) and the 360-bp chIFN- probe (B). The P3-derived RNA samples
analyzed were isolated from uninfected cells (lane 1); IBV-infected cells (lane 2); cells containing D-RNAs IBV-Vec-IFN-PmaCI, IBV-Vec-
IFN--SnaBI, IBV-Vec--NFIPmaCI, and IBV-Vec--NFISnaBI (lanes 3 to 6, respectively); and in vitro T7-derived IBV-Vec-IFN-PmaCI
transcripts (lane 7). Arrows indicate IBV gRNA, sg mRNAs 2 to 6, TAS-chIFN--containing D-RNAs, and D-RNA-derived chIFN-mRNAs. The
RNAs detected between sg mRNAs 4 and 5 are observed routinely for all strains of IBV, as originally identified by Stern and Kennedy (38), and
are of unknown origin. The RNAs migrating slower than IBV sg mRNA 2 were later shown to be new IBV-derived D-RNAs. The expected position
of the full-length native cellular mRNA for chIFN- (1,040 nt) is indicated on panel B. S, spike glycoprotein; E, small membrane protein; M,
integral membrane protein; N, nucleocapsid protein.
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FIG. 3. Northern blot analysis of IBV-specific RNAs following serial passage of D-RNAs IBV-Vec-IFN-PmaCI and IBV-Vec-IFN-SnaBI.
RNAs isolated from P0 to P6 CK cells were analyzed for the presence of D-RNAs IBV-Vec-IFN-PmaCI (A to C) and IBV-Vec-IFN-SnaBI (D
to F). IBV-derived RNAs were detected by using the 309-bp IBV 3-UTR probe (A and D), the 209-bp IBV 5-UTR probe (B and E), and the
360-bp chIFN- probe (C and F). The RNA samples analyzed were isolated from IBV-infected cells (lane 1), uninfected cells (lane 2), and P0 to
P6 cells containing D-RNAs IBV-Vec-IFN-PmaCI (A to C, lanes 3 to 9) and IBV-Vec-IFN-SnaBI (D to F, lanes 3 to 9). (A to C) Lanes 10
correspond to in vitro T7-derived IBV-Vec-IFN-PmaCI. Arrows indicate IBV gRNA, sg mRNAs, and TAS-chIFN--containing D-RNAs. The
RNAs migrating slower than IBV sg mRNA 2, detected in RNA samples isolated from P3 to P6 cells (A, B, D, and E, lanes 6), are new IBV-derived
D-RNAs. Analysis of RNA following passage of IBV-Vec-IFN-SnaBI identified the D-RNA-derived chIFN- mRNA (F, lanes 5 to 8). S, spike
glycoprotein; E, small membrane protein; M, integral membrane protein; N, nucleocapsid protein.
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cells, than any of the controls (Fig. 4A). In contrast, medium
from cells containing D-RNAs IBV-Vec--NFIPmaCI and
IBV-Vec--NFISnaBI did not induce larger amounts of NO
than the controls. Controls involved medium from uninfected
CK and IBV-infected CK cells. The amounts of NO induced by
using medium from control samples and from cells containing
D-RNAs with the TAS-chIFN- insert in the incorrect orien-
tation were similar and likely to result from the presence of
IFN- or IFN-	. The IFN- bioassay also detects IFN- and
IFN-	, previously shown to be produced by IBV-infected cells
(16, 28, 29).
To confirm that the NO detected by the IFN- bioassay was
due to the induction of HD11 cells by IFN-, and not by IFN-
and IFN-	, which also stimulate the production of NO, a
neutralizing bioassay was carried out. Samples of cell medium
were preincubated with the chIFN--neutralizing MAb 1E-12
and analyzed with the IFN- bioassay. Samples were also pre-
incubated with medium and Ab CC305, an isotype control Ab
against bovine granulocyte-macrophage colony-stimulating
factor. For comparative purposes, recombinant chIFN- was
included as a positive control sample. NO induction, using
medium from cells containing D-RNAs IBV-Vec-IFN-
PmaCI and IBV-Vec-IFN-SnaBI, with the TAS-chIFN-
sequence in the correct orientation, was reduced following
preincubation of the samples with the neutralizing MAb 1E-12
(Fig. 4B). The amount of neutralizing MAb 1E-12 used was
sufficient to neutralize all the chIFN- in the solution. To
confirm this, the neutralizing activity of the MAb had been
titrated before use in this experiment. Levels of remaining
activity were assumed to be due to IFN- and IFN-	. These
levels were consistent with those seen in a previous study using
this neutralizing MAb (19). A similar reduction in NO induc-
tion was observed when the recombinant chIFN- was prein-
cubated with the MAb 1E-12. In contrast, the NO induced by
using medium from cells containing D-RNAs IBV-Vec--
NFIPmaCI and IBV-Vec--NFISnaBI, with the TAS-chIFN-
sequence in the incorrect orientation, was not affected by the
addition of the neutralizing MAb 1E-12. This indicated that
the NO detected resulted from induction with chicken IFN-
or IFN-	 rather than chIFN- in the cell medium (Fig. 4B).
These results showed that the NO induction observed by using
samples taken from cells containing D-RNAs IBV-Vec-IFN-
PmaCI and IBV-Vec-IFN-SnaBI resulted from the presence
of chIFN- in the cell medium and confirmed that the D-
RNAs expressed biologically active chIFN-.
Induction of NO, using medium from cells containing D-
RNAs IBV-Vec-IFN-PmaCI and IBV-Vec-IFN-SnaBI, was
observed from P0 and increased to P4, followed by a decrease
in NO at P5 to P6. This indicated that the amounts of chIFN-
expressed increased upon serial passage of the D-RNAs, with
a peak of activity in P4 CK cells followed by a decrease in
activity (Fig. 4A). This result correlated with the Northern blot
analyses in which the amounts of the D-RNAs and one of the
D-RNA-derived chIFN- mRNAs followed the same pattern
over serial passage. Results of the bioassay also showed that
there were no significant differences in the amounts of NO
induced whether the samples came from cells containing TAS-
chIFN- inserted into the PmaCI or from cells containing
TAS-chIFN- inserted into the SnaBI site of CD-61 (Fig. 4A),
indicating that both D-RNAs expressed similar amounts of
chIFN-.
In ovo rescue of chIFN--containing D-RNAs. Previous
work to determine whether IBV D-RNAs could be passaged in
vivo by using embryonated eggs (in ovo) had required subse-
quent passage of a D-RNA expressing chloramphenicol acetyl-
transferase (CAT) on indicator CK cells. Subsequent analysis
of cell lysates demonstrated the presence of CAT (5, 11). A
limitation of these experiments was that replication may not
have occurred in ovo and that rescue on the CK cells could
have resulted from virus and D-RNA present in the allantoic
fluid from the initial inoculum, although rescue following di-
lution in the allantoic fluid would be indicative of replication in
FIG. 4. Analysis of IFN activity in cell medium following in vitro
passage of chIFN--containing D-RNAs. (A) NO detected from HD11
cells, following stimulation with cell medium samples from uninfected
cells (sample 1); IBV-infected cells (six passages) (sample 2); and P0 to
P6 cells containing D-RNAs IBV-Vec-IFN-PmaCI, IBV-Vec-IFN-
SnaBI, IBV-Vec--NFIPmaCI, and IBV-Vec--NFISnaBI (samples
3 to 6, respectively). (B) chIFN--neutralizing bioassays using anti-
chIFN- MAb 1E-12. Cell medium samples were preincubated for 2 h
with medium alone (black bars), MAb 1E-12 (dark grey bars), or the
isotype control Ab CC305 (light grey bars). Antibodies were diluted
1:1,000 for the assay. Ab-treated samples, analyzed for their ability to
induce NO from HD11 cells, were from IBV-infected cells (sample 1),
cells containing D-RNAs IBV-Vec-IFN-PmaCI and IBV-Vec-IFN-
SnaBI (used at 1:8 dilutions) (samples 2 and 3, respectively), cells
containing D-RNAs IBV-Vec--NFIPmaCI and IBV-Vec--
NFISnaBI (samples 4 and 5, respectively), medium alone (sample 6),
and recombinant chIFN- at 1:125 and 1:250 dilutions (samples 7 and
8, respectively). Nitrite resulting from the induced NO in the HD11
cell medium samples was quantified by using a variation of the Griess
assay, measuring absorbance at 543 nm. The histograms represent the
midpoints taken from the linear portions of titration curves calculated
from the means of results for triplicates of each sample (A) and the
means of results for triplicate samples (
 standard errors) (B). OD543,
optical density at 543 nm.
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ovo. The secretion of chIFN- into cell medium following
expression from the D-RNAs described in this work provided
a means of determining whether IBV D-RNAs can be repli-
cated in ovo.
Following serial passage of D-RNAs IBV-Vec-IFN-PmaCI
and IBV-Vec-IFN-SnaBI, the largest amounts of D-RNA
detected with concomitant expression of chIFN- occurred in
P4 cells (Fig. 3 and 4). Consequently, we decided to use prog-
eny virus (V4) containing the D-RNAs from P3 cells to deter-
mine whether the D-RNAs could be rescued in ovo. Virus (V4)
from P3 cells, representing virus that was one passage away
from peak chIFN- activity, was used to infect 10-day-old spe-
cific-pathogen-free embryonated eggs. At 16 h postinoculation,
allantoic fluid was clarified and used to infect CK cells to
confirm that the D-RNAs could be passaged from embryo-
nated eggs. The fluid was also used for chIFN- bioassays to
analyze for the presence of any chIFN- resulting from the
replication of the D-RNAs in ovo.
IFN- bioassays showed that allantoic fluid and CK cell
medium samples, following passage of D-RNAs IBV-Vec-
IFN-PmaCI and IBV-Vec-IFN-SnaBI, contained amounts
of chIFN- that were up to 64-fold and 10-fold larger, respec-
tively, as measured by NO levels, than those of the controls
(Fig. 5A), indicating that the D-RNAs had replicated in ovo.
The amounts of NO induced following infection with IBV only
and passage of D-RNAs containing the TAS-chIFN- gene
construct in the antisense orientation were all similar, with NO
induction presumably due to the presence of IFN- or IFN-	.
The amounts of chIFN-, as measured by NO levels, in allan-
toic fluid following in ovo passage of D-RNAs IBV-Vec-IFN-
PmaCI and IBV-Vec-IFN-SnaBI were larger than those
found in CK cell medium following subsequent in vitro passage
of the D-RNAs. This result was anticipated, as the in ovo
passage was equivalent to P4 and CK passage was equivalent to
P5 when equated with in vitro passage of the D-RNAs.
A neutralizing IFN- bioassay was again performed to con-
firm that the NO induced resulted from IFN- and not from
IFN- and IFN-	. Allantoic fluid and CK cell medium samples
were preincubated with MAb 1E-12, medium, and the isotype
control Ab CC305 for 2 h prior to the IFN- bioassay (Fig. 5B).
The amounts of NO induced by using samples from embryo-
nated eggs (Fig. 5B, samples 1 and 2) and CK cells (Fig. 5B,
samples 9 and 10) infected with IBV containing D-RNAs IBV-
Vec-IFN-PmaCI and IBV-Vec-IFN-SnaBI were similar for
both D-RNAs both in ovo and in vitro and were similarly
reduced following preincubation with MAb 1E-12. A similar
reduction in NO induction was observed following preincuba-
tion of recombinant chIFN- with MAb 1E-12 (Fig. 5B, sample
7), indicating that the IFN activities detected in the allantoic
fluid and CK cell medium samples resulted from IFN-. In
contrast, the amounts of NO induced by using samples from
embryonated eggs and CK cells infected with IBV containing
D-RNAs IBV-Vec--NFIPmaCI and IBV-Vec--NFISnaBI
and from IBV infection alone were not reduced following
preincubation with MAb 1E-12 (Fig. 5B). This indicated that
the IFN activities observed following in ovo passage of these
D-RNAs and IBV alone resulted from the induction of IFN-
and IFN-	 and not from IFN-.
These results confirmed that D-RNAs IBV-Vec-IFN-
PmaCI and IBV-Vec-IFN-SnaBI expressed biologically ac-
tive chIFN- following helper virus-dependent replication in
ovo.
DISCUSSION
The construction of a series of IBV-based D-RNAs contain-
ing the chIFN- sequence under the control of an IBV TAS
FIG. 5. Analysis of IFN activity in allantoic fluid following in ovo
passage of chIFN--containing D-RNAs. The chIFN--containing D-
RNAs were initially passaged in embryonated eggs, and progeny virus
containing the D-RNAs in the allantoic fluid was passaged on indicator
CK cells. (A) NO detected from HD11 cells following stimulation with
allantoic fluid (dark grey bars) or CK cell medium (light grey bars)
from passage of D-RNAs IBV-Vec-IFN-PmaCI, IBV-Vec-IFN-
SnaBI, IBV-Vec--NFIPmaCI, and IBV-Vec--NFISnaBI (samples
1 to 4, respectively); IBV-infected cells (sample 5); and uninfected cells
(sample 6). The histogram represents the midpoints taken from the
linear portions of titration curves calculated from the means (
 stan-
dard errors) of results for triplicates of each sample. (B) chIFN--
neutralizing bioassays in which samples, preincubated for 2 h with
medium alone (black bars), MAb 1E-12 (dark grey bars), or CC305
(light grey bars), were analyzed for their ability to induce NO from
HD11 cells consisted of allantoic fluid (samples 1 to 6); CK cell media
(samples 9 to 14); recombinant chIFN- diluted 1:2,000 (sample 7);
and media alone (sample 8). Samples 1 to 4 and 9 to 12 were from
allantoic fluid and CK cell medium, respectively, following passage of
D-RNAs IBV-Vec-IFN-PmaCI (diluted 1:8), IBV-Vec-IFN-SnaBI
(diluted 1:8), IBV-Vec--NFIPmaCI, and IBV-Vec--NFISnaBI, re-
spectively. Samples 5 to 6 and 13 to 14 were from allantoic fluid and
CK cell medium, respectively, from cells infected with IBV (5 and 13)
or uninfected cells (6 and 14). Antibodies were diluted 1:1,000 for the
assay. The histogram represents the means (
 standard errors) of
results for triplicate samples. OD543, optical density at 543 nm.
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has been described. We have shown that IBV D-RNAs con-
taining the chIFN- gene were incorporated into virus particles
and expressed biologically active chIFN- in vitro and in vivo.
Serial passage of the chIFN--containing D-RNAs followed
the same pattern of both D-RNA replication and heterologous
protein expression that we have previously observed for the
expression of the heterologous reporter genes encoding CAT
(39) and luciferase (13) from IBV-based D-RNAs. Both de-
tection of the D-RNA and expression of chIFN- increased
from P0 to P4 and decreased thereafter. No differences in the
amounts of D-RNA detected or in chIFN- activities were
observed whether the TAS-chIFN- cassette was inserted in
domain I (IBV-Vec-IFN-SnaBI), interrupting the D-RNA-
specific ORF, or domain III (IBV-Vec-IFN-PmaCI), not in-
terrupting the D-RNA-specific ORF, of D-RNA CD-61.
A D-RNA-derived chIFN- mRNA synthesized from IBV-
Vec-IFN-SnaBI was detectable upon serial passage of the
D-RNA (Fig. 2B and 3F). Although a D-RNA-derived
chIFN- mRNA synthesized from IBV-Vec-IFN-PmaCI was
initially detected (Fig. 2B), it was synthesized in smaller
amounts, in relation to the D-RNA, than the mRNA from
IBV-Vec-IFN-SnaBI. The observed levels of subgenomic
RNAs (sgRNAs) transcribed, under the control of the gene 5
TAS, from CD-61-derived D-RNAs were far less than the
amounts observed for the transcription of sg mRNA 5 from
genomic RNA. Similar observations have been made following
transcription of sgRNAs from other coronavirus-derived D-
RNAs. The altered transcription levels may be connected to
the observation that D-RNAs may replicate in a manner anal-
ogous to the transcription of sg mRNAs from genomic RNA
(40), thereby affecting the levels of transcription of D-RNA-
derived sgRNAs, or the levels may result from the altered
context of the TAS within the D-RNA. The sequences flanking
the TASs of heterologous genes in transmissible gastroenteritis
virus-derived D-RNAs have been shown to alter the transcrip-
tion of D-RNA-derived sgRNAs (1). The amounts of chIFN-
secreted from cells containing the D-RNAs were similar, as
observed from the induction of NO from HD11 cells, indicat-
ing that the D-RNAs expressed similar amounts of active
chIFN-. Similar results were observed for the expression of
	-glucuronidase (GUS) from a transmissible gastroenteritis
virus-based D-RNA, in which the D-RNA-derived GUS
mRNA was transcribed in smaller amounts in P2 cells than in
P5 cells, although the amounts of GUS protein expressed were
the same (2).
Although its main role is in driving a Th1 cell-mediated
response against intracellular pathogens, including viruses,
IFN- can have a direct antiviral effect. Like IFN- and IFN-	,
but to a much lesser extent, it can induce oligoadenylate syn-
thetase and RNA-dependent protein kinase PKR, both impor-
tant components of IFN-induced antiviral responses (8, 14,
34). It was therefore possible that expression of chIFN- from
the D-RNAs might interfere with replication of the helper
virus. A murine IFN--containing D-RNA of the murine coro-
navirus mouse hepatitis virus (MHV) expressed murine IFN-
that resulted in a slight reduction in virus titer (0.5 log10) at low
multiplicities of infection, suggesting that the murine IFN-
had a weak antiviral activity (42). In contrast, we observed no
significant differences in virus titers resulting from expression
of the chIFN- from any of the IBV D-RNAs (data not
shown), suggesting that the chIFN- did not have an apprecia-
ble antiviral effect on the helper IBV.
The murine IFN--containing MHV D-RNA was not de-
tected beyond P4 (42), whereas the IBV-based chIFN--con-
taining D-RNAs were rescued for at least six passages. This
observation reflects our previous studies on the expression of
heterologous genes from IBV-CD-61-based D-RNAs. Expres-
sion of heterologous genes or coronavirus-derived genes from
other coronavirus D-RNAs also resulted in loss of the D-
RNAs. For example, expression of CAT and hemagglutinin
esterase from MHV D-RNAs was not detected beyond P2 (20)
and P3 (43), respectively. The most likely explanation for the
instability of coronavirus D-RNAs expressing heterologous
genes is intolerance of the heterologous sequence within the
D-RNA. D-RNAs evolve by the removal of unnecessary se-
quences. Therefore, the presence of a heterologous sequence
may impart some innate instability into the RNA or affect
replication and/or packaging of the D-RNA; i.e., D-RNAs
containing heterologous or nonrequired sequences are less
fitted for replication than D-RNAs with minimal required se-
quences. We detected additional RNA species, which were
larger than the chIFN--containing D-RNAs and IBV sg
mRNA 2, from P3 which increased in amount upon serial
passage. The new RNAs were not detected by the chIFN--
specific probe but by the IBV 5 probe, showing that they
contained sequences derived from the 5 end of the IBV ge-
nome and were therefore new D-RNAs. As determined from
their sizes, the new D-RNAs were not from the loss of the
chIFN- sequence. An explanation for the loss of the chIFN-
-containing D-RNAs beyond P4 was the generation of more
stable D-RNAs from P3 that eventually resulted, due to com-
petition, in the loss of the chIFN--containing D-RNAs.
Overall, we have demonstrated that in vitro passage of the
chIFN--containing D-RNAs resulted in expression of biolog-
ically active chIFN- secreted into cell culture medium. This
observation allowed us to demonstrate that IBV D-RNAs can
be replicated in ovo from the presence of biologically active
chIFN- secreted into the allantoic fluid and subsequent pas-
sage on indicator CK cells.
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